Does the media prefer SLDB or LEGN?

In the previous week, Solid Biosciences and Solid Biosciences both had 5 articles in the media. Solid Biosciences' average media sentiment score of 0.82 beat Legend Biotech's score of -0.14 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RCUS or SLDB?

In the previous week, Arcus Biosciences had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 6 mentions for Arcus Biosciences and 5 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.82 beat Arcus Biosciences' score of 0.71 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SLDB or VCYT?

In the previous week, Veracyte had 5 more articles in the media than Solid Biosciences. MarketBeat recorded 10 mentions for Veracyte and 5 mentions for Solid Biosciences. Veracyte's average media sentiment score of 1.29 beat Solid Biosciences' score of 0.82 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SLDB or CLDX more profitable?

Celldex Therapeutics' return on equity of -52.35% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% Celldex Therapeutics N/A -52.35% -47.61%

Does the media prefer SLDB or CLDX?

In the previous week, Solid Biosciences had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Solid Biosciences and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.90 beat Solid Biosciences' score of 0.82 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SLDB or GMTX?

Solid Biosciences presently has a consensus target price of $17.40, suggesting a potential upside of 87.10%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Solid Biosciences is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.82 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, SLDB or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.91 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is SLDB or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% Gemini Therapeutics N/A -38.78% -35.88%

Does the media prefer SLDB or GMTX?

In the previous week, Solid Biosciences had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Solid Biosciences and 1 mentions for Gemini Therapeutics. Solid Biosciences' average media sentiment score of 0.82 beat Gemini Therapeutics' score of 0.75 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gemini Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Solid Biosciences (SLDB) Competitors

$9.30 +0.20 (+2.20%)

As of 08/21/2026 04:00 PM Eastern

Compare

SLDB vs. LEGN, RCUS, VCYT, CLDX, and GMTX

Should you buy Solid Biosciences stock or one of its competitors? Solid Biosciences's main competitors and comparable companies include Legend Biotech (LEGN), Arcus Biosciences (RCUS), Veracyte (VCYT), Celldex Therapeutics (CLDX), and Gemini Therapeutics (GMTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Solid Biosciences compare to Legend Biotech?

Solid Biosciences (NASDAQ:SLDB) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

In the previous week, Solid Biosciences and Solid Biosciences both had 5 articles in the media. Solid Biosciences' average media sentiment score of 0.82 beat Legend Biotech's score of -0.14 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solid Biosciences has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Legend Biotech	-7.21%	-8.71%	-5.40%

Solid Biosciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Solid Biosciences has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Legend Biotech	$1.03B	3.94	-$296.80M	-$0.25	N/A

Solid Biosciences presently has a consensus target price of $17.40, indicating a potential upside of 87.10%. Legend Biotech has a consensus target price of $52.29, indicating a potential upside of 139.62%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

Summary

Solid Biosciences beats Legend Biotech on 9 of the 14 factors compared between the two stocks.

How does Solid Biosciences compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Solid Biosciences has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Solid Biosciences' return on equity of -71.35% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Solid Biosciences	N/A	-71.35%	-60.58%

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by insiders. Comparatively, 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Arcus Biosciences has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.41, suggesting that its stock price is 141% more volatile than the broader market.

Arcus Biosciences currently has a consensus target price of $37.80, indicating a potential upside of 25.41%. Solid Biosciences has a consensus target price of $17.40, indicating a potential upside of 87.10%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Solid Biosciences is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Solid Biosciences has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	15.54	-$353M	-$3.90	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

In the previous week, Arcus Biosciences had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 6 mentions for Arcus Biosciences and 5 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.82 beat Arcus Biosciences' score of 0.71 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solid Biosciences beats Arcus Biosciences on 10 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to Veracyte?

Solid Biosciences (NASDAQ:SLDB) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

81.5% of Solid Biosciences shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 1.6% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Solid Biosciences has a beta of 2.41, suggesting that its stock price is 141% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

In the previous week, Veracyte had 5 more articles in the media than Solid Biosciences. MarketBeat recorded 10 mentions for Veracyte and 5 mentions for Solid Biosciences. Veracyte's average media sentiment score of 1.29 beat Solid Biosciences' score of 0.82 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences presently has a consensus target price of $17.40, indicating a potential upside of 87.10%. Veracyte has a consensus target price of $54.33, indicating a potential upside of 28.42%. Given Solid Biosciences' higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Veracyte has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Veracyte	$517.15M	6.58	$66.35M	$1.41	30.01

Veracyte has a net margin of 20.37% compared to Solid Biosciences' net margin of 0.00%. Veracyte's return on equity of 9.26% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Veracyte	20.37%	9.26%	8.61%

Summary

Veracyte beats Solid Biosciences on 10 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to Celldex Therapeutics?

Solid Biosciences (NASDAQ:SLDB) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Solid Biosciences currently has a consensus price target of $17.40, indicating a potential upside of 87.10%. Celldex Therapeutics has a consensus price target of $56.08, indicating a potential upside of 38.89%. Given Solid Biosciences' higher possible upside, analysts plainly believe Solid Biosciences is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

81.5% of Solid Biosciences shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Solid Biosciences has higher earnings, but lower revenue than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Celldex Therapeutics	$1.54M	2,059.12	-$258.76M	-$4.35	N/A

Solid Biosciences has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

In the previous week, Solid Biosciences had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Solid Biosciences and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.90 beat Solid Biosciences' score of 0.82 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celldex Therapeutics' return on equity of -52.35% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Summary

Solid Biosciences and Celldex Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Solid Biosciences compare to Gemini Therapeutics?

Solid Biosciences (NASDAQ:SLDB) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics' return on equity of -38.78% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Solid Biosciences presently has a consensus target price of $17.40, suggesting a potential upside of 87.10%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Solid Biosciences is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Solid Biosciences has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Solid Biosciences had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Solid Biosciences and 1 mentions for Gemini Therapeutics. Solid Biosciences' average media sentiment score of 0.82 beat Gemini Therapeutics' score of 0.75 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gemini Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solid Biosciences beats Gemini Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Solid Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLDB vs. The Competition

Export

Metric	Solid Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$997.19M	$4.01B	$7.37B	$12.83B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-4.87	11.62	272.33	24.21
Price / Sales	N/A	1,341.06	625.25	96.46
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	4.08	17.38	11.25	6.42
Net Income	-$174.32M	-$22.72M	$3.47B	$348.89M
7 Day Performance	1.09%	3.29%	2.09%	0.08%
1 Month Performance	16.54%	8.23%	6.64%	3.88%
1 Year Performance	56.83%	55.05%	25.02%	16.98%

Solid Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLDB Solid Biosciences	2.4156 of 5 stars	$9.30 +2.2%	$17.40 +87.1%	+56.8%	$997.19M	N/A	N/A	100	News Coverage Analyst Forecast Gap Up
LEGN Legend Biotech	2.8287 of 5 stars	$20.27 -1.8%	$52.29 +157.9%	-38.6%	$3.84B	$1.03B	N/A	2,965	Analyst Downgrade Analyst Revision
RCUS Arcus Biosciences	2.9924 of 5 stars	$28.84 -0.4%	$37.80 +31.1%	+186.8%	$3.69B	$247M	N/A	500
VCYT Veracyte	4.3795 of 5 stars	$42.60 -4.7%	$54.33 +27.5%	+36.5%	$3.59B	$517.15M	30.21	790	News Coverage Positive News
CLDX Celldex Therapeutics	2.7327 of 5 stars	$42.61 -5.0%	$55.46 +30.2%	+79.8%	$3.52B	$1.54M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLDB) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solid Biosciences (SLDB) Competitors

SLDB vs. LEGN, RCUS, VCYT, CLDX, and GMTX

How does Solid Biosciences compare to Legend Biotech?

Summary

How does Solid Biosciences compare to Arcus Biosciences?

Summary

How does Solid Biosciences compare to Veracyte?

Summary

How does Solid Biosciences compare to Celldex Therapeutics?

Summary

How does Solid Biosciences compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solid Biosciences (SLDB) Competitors

SLDB vs. LEGN, RCUS, VCYT, CLDX, and GMTX

How does Solid Biosciences compare to Legend Biotech?

Does the media prefer SLDB or LEGN?

Is SLDB or LEGN more profitable?

Which has more volatility and risk, SLDB or LEGN?

Do institutionals and insiders believe in SLDB or LEGN?

Which has better earnings and valuation, SLDB or LEGN?

Do analysts prefer SLDB or LEGN?

Summary

How does Solid Biosciences compare to Arcus Biosciences?

Is RCUS or SLDB more profitable?

Do insiders & institutionals believe in RCUS or SLDB?

Which has more risk and volatility, RCUS or SLDB?

Do analysts prefer RCUS or SLDB?

Which has better valuation & earnings, RCUS or SLDB?

Does the media refer more to RCUS or SLDB?

Summary

How does Solid Biosciences compare to Veracyte?

Do institutionals & insiders have more ownership in SLDB or VCYT?

Which has more risk and volatility, SLDB or VCYT?

Does the media prefer SLDB or VCYT?

Do analysts recommend SLDB or VCYT?

Which has stronger valuation & earnings, SLDB or VCYT?

Is SLDB or VCYT more profitable?

Summary

How does Solid Biosciences compare to Celldex Therapeutics?

Do analysts prefer SLDB or CLDX?

Do insiders & institutionals have more ownership in SLDB or CLDX?

Which has stronger earnings & valuation, SLDB or CLDX?

Which has more risk and volatility, SLDB or CLDX?

Does the media prefer SLDB or CLDX?

Is SLDB or CLDX more profitable?

Summary

How does Solid Biosciences compare to Gemini Therapeutics?

Which has higher valuation and earnings, SLDB or GMTX?

Is SLDB or GMTX more profitable?

Do analysts recommend SLDB or GMTX?

Which has more volatility and risk, SLDB or GMTX?

Do institutionals and insiders hold more shares of SLDB or GMTX?

Does the media prefer SLDB or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools